Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - aluminium powder - cutaneous spray powder - 4 %w/w - aluminium agents - bovine, canine, equine - food, feline, fowl, ovine, porcine - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

vetoquinol ireland limited - aluminium - cutaneous spray, powder - 4 percent weight/weight - aluminium agents - cats, cattle, dogs, horses, other birds, pigs, sheep - antibacterial

New Zealand - English - Medsafe (Medicines Safety Authority)

world agencies pty limited (cussons new zealand ltd) - aluminium hydroxide gel dried 22.5%{relative}; calcium carbonate 44.94%{relative}; magnesium carbonate 20%{relative} - powder for oral solution - active: aluminium hydroxide gel dried 22.5%{relative} calcium carbonate 44.94%{relative} magnesium carbonate 20%{relative}

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

memphis chemicals - aluminium, boric acid - mouthwash, powder for solution - 65, 25 g

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

multicrop (aust.) pty. ltd. - aluminium ammonium sulfate - soluble powder - aluminium ammonium sulfate mineral-aluminium active 999.9 g/kg - repellent - dogs etc - flower seedling | fruit crop or tree | hard surface pest control | home garden use - general | lawn | shrub, tree | vegetable se - bird | cat | dog | rabbit | rodent, rat or mouse | black rat/mouse | brown rat/mouse | mouse | rat | rodent | roof rat

New Zealand - English - Ministry for Primary Industries

envirofume limited - aluminium phosphide - aluminium phosphide 570 g/kg - insecticide

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ceftazidime pentahydrate, quantity: 2329.6 mg (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - sever infections in general: for expample septicaemia (including neonatal sepsis), bacteraemia, patients in intensive care units with specific problems, e.g infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis, bronchitis. - sever ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - ceftazidime pentahydrate, quantity: 1164.8 mg (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - sever infections in general: for expample septicaemia (including neonatal sepsis), bacteraemia, patients in intensive care units with specific problems, e.g infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis, bronchitis. - sever ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: saccharin; vanillin - treatment of hyperkalaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - calcium polystyrene sulfonate, quantity: 999.3 mg/g - powder - excipient ingredients: vanillin; saccharin - calcium resonium is an ion-exchange resin. it is recommended for the treatment of hyperkalaemia associated with anuria and severe oliguria.,it is also used to treat hyperkalaemia in patients requiring dialysis and in patients on regular haemodialysis or on prolonged peritoneal dialysis.